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Abstract
Objective To examine the relation between the type of stress ulcer
prophylaxis administered and the risk of postoperative pneumonia in
patients undergoing coronary artery bypass grafting.
Design Retrospective cohort study.
Setting Premier Research Database.
Participants: 21 214 patients undergoing coronary artery bypass graft
surgery between 2004 and 2010; 9830 (46.3%) started proton pump
inhibitors and 11 384 (53.7%) started H2 receptor antagonists in the
immediate postoperative period.
Main outcome measure Occurrence of postoperative pneumonia,
assessed using appropriate diagnostic codes.
Results Overall, 492 (5.0%) of the 9830 patients receiving a proton
pump inhibitor and 487 (4.3%) of the 11 384 patients receiving an H2
receptor antagonist developed postoperative pneumonia during the index
hospital admission. After propensity score adjustment, an elevated risk
of pneumonia associated with treatment with proton pump inhibitors
compared with H2 receptor antagonists remained (relative risk 1.19, 95%
confidence interval 1.03 to 1.38). In the instrumental variable analysis,
use of a proton pump inhibitor (compared with an H2 receptor antagonist)
was associated with an increased risk of pneumonia of 8.2 (95%
confidence interval 0.5 to 15.9) cases per 1000 patients.
Conclusions Patients treated with proton pump inhibitors for stress
ulcer had a small increase in the risk of postoperative pneumonia
compared with patients treated with H2 receptor antagonists; this risk
remained after confounding was accounted for using multiple analytic
approaches.
Introduction
Nosocomialpneumoniaisacommoncomplicationaftercardiac
surgery, affecting between 2% and 10% of patients.
1-5 It carries
a substantial risk of death; estimates of the mortality rate range
from20%to50%.
1-5Therefore,identificationofmodifiablerisk
factors and strategies to prevent pneumonia following cardiac
surgery are urgently needed.
Acid suppressive drugs are often used after cardiac surgery to
prevent the formation of stress ulcers and gastrointestinal
bleeding in these critically ill patients. These agents raise the
gastrointestinalpH,whichcanresultinbacterialproliferation
6-9;
this, in turn, may predispose patients to tracheal colonization
and pneumonia.
6 10 Several studies have associated acid
suppressive drugs with an increased risk of pneumonia in both
inpatient and outpatient settings,
11-15 although results are
conflicting.
16 17
Thetwomostcommonlyusedclassesofacidsuppressivedrugs,
protonpumpinhibitorsandH2receptorantagonists,mayconfer
differential risks for pneumonia in cardiac surgical patients. A
single center, retrospective study of cardiothoracic surgical
patients found treatment with pantoprazole (a proton pump
inhibitor) to be associated with a markedly elevated risk of
nosocomialpneumonia(adjustedoddsratio2.7,95%confidence
interval 1.1 to 6.7) compared with ranitidine (an H2 receptor
antagonist).
10 This finding has not, to date, been replicated.
Given the widespread use of acid suppressive drugs in cardiac
surgical patients, the importance of the complication of
nosocomial pneumonia, the strong difference in risk observed
in this previous study, and the remaining uncertainty about the
true differential risk between these agents, we examined the
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Research
RESEARCHeffect of treatment with proton pump inhibitors versus H2
receptor antagonists on the risk of nosocomial pneumonia in
postoperative cardiac surgical patients by using a large hospital
inpatient database in the United States.
Methods
Data source
StudydatacamefromthePremierResearchDatabase,ahospital
administrative database that contains information on
approximatelyonesixthofallhospitaladmissionsintheUnited
States. The database contains a complete census of inpatients
fromapproximately500hospitalsfromacrosstheUnitedStates
(numbers vary slightly by year). Preliminary analysis done by
the Premier organization comparing characteristics of patients’
andhospitals’forPremierhospitalswiththosefromtheNational
Hospital Discharge survey suggests that the profile of patients
treatedatPremierhospitalsissimilartothosetreatednationally
(Statement of Work Document, Premier Inc, 2012). It contains
information for all patients treated at the included hospitals,
independent of payer (Medicaid, Medicare, or commercial
insurance).Premiercollectsdatafrommemberhospitalsthrough
its informatics products and then provides information back to
hospitals for benchmarking purposes. Member hospitals pay
Premier for these services. Member hospitals are primarily
non-profit, non-governmental, community and teaching
hospitals. The database includes charges for all drugs,
procedures,anddiagnostictestsduringeachhospitaladmission.
It also includes patients’ demographic characteristics and
hospital characteristics, discharge diagnoses, and discharge
status. Data are routinely audited, verified, and validated to
ensure that the use of supplies and other hospital resources are
withinanacceptablerange,butPremierdoesnotdirectlyverify
thatsubmitteddatamatchindividualpatients’medicalrecords.
18
Several previous studies have used Premier data to study
perioperative drug use and health outcomes.
18-20
Cohort
The cohort consisted of patients aged 18 years or older who
underwent the most common cardiac surgical procedure,
coronary artery bypass graft surgery, identified by code 36.1,
oranysubcodethereof,fromICD-9(internationalclassification
of diseases, 9th revision) between January 1, 2004 and
December 31, 2010. For the main analysis, we included only
those patients who had coronary artery bypass grafting on the
third day of hospital admission or thereafter. We did this to
obtain a preoperative period in which to measure patients’
baseline comorbidities and other risk factors; these factors may
affect both the choice of agent for stress ulcer prophylaxis and
risk of pneumonia and thus confound the planned analysis. To
ensure that we did not include in our analysis any patients who
had pneumonia at the time of admission to the hospital, we
excludedthosewhowereexposedtosystemicantibioticsbefore
the day of surgery. We also excluded patients exposed to either
proton pump inhibitors or H2 receptor antagonists before the
day of surgery to isolate the effect of the type of stress ulcer
prophylaxis given in the immediate postoperative period. We
further limited our analysis to those patients who started either
a proton pump inhibitor or an H2 receptor antagonist, but not
both, on postoperative days 1, 2, or both and who survived to
postoperativeday3orbeyond.Asingledoseofacidsuppressive
drug is commonly administered immediately before surgery to
lessen the risk of aspiration on induction of anesthesia; as the
focus of this study was the risk associated with stress ulcer
prophylaxis in the postoperative period, we assigned exposure
status independently of the type of acid suppression drug
administered on the day of surgery.
Classification of drug exposure and study
outcome
We defined exposure to proton pump inhibitor by one or more
charges on postoperative days 1 or 2 for omeprazole,
lansoprazole, esomeprazole, pantoprazole, or rabeprazole. We
defined exposure to H2 receptor antagonist by charges on
postoperativedays1or2forcimetidine,ranitidine,famotidine,
or nizatidine.
The study outcome was the development of postoperative
pneumoniaduringtheindexhospitaladmissionandwasassessed
by the presence of the ICD-9 diagnosis codes of 481 to 486 or
507 (and any subcode thereof) among the reported discharge
diagnoses. The exclusion of patients with systemic antibiotics
before surgery would indicate that the pneumonia developed
while the patient was in hospital, rather than being a condition
present on admission. We also assessed two secondary
outcomes:postoperativeuppergastrointestinalhemorrhageand
in-hospital death. We defined postoperative upper
gastrointestinal hemorrhage on the basis of the presence of
appropriate diagnosis and procedure codes. To ensure that any
reported hemorrhage occurred postoperatively, we further
required a charge for an esophagogastroduodenoscopy during
the postoperative follow-up period.
Esophagogastroduodenoscopiesareroutinelydonefordiagnostic
and therapeutic purposes for patients with severe upper
gastrointestinal bleeding.
Patient and hospital level covariates
We extracted five groups of potential confounders from the
database: demographic characteristics, surgery characteristics,
chroniccomorbidconditions,markersoftheseverityofcardiac
or coexisting conditions, and hospital characteristics. The
demographic characteristics considered included age on
admission,ethnicity(classifiedaswhite,black,orother),marital
status (classified as married, single, or unknown), and sex.
Surgery characteristics included type of admission (classified
as emergency, elective, or unknown); number of bypass grafts
(classified as one, two, three, or four or more); whether the
patient received a mammary artery graft; whether the patient
hadapreviouscoronaryarterybypassgraft;whetherthesurgery
was done using cardiopulmonary bypass; whether the patient
received a transfusion of packed red blood cells; whether the
patient received an intra-aortic balloon pump; whether the
patient received an aortic, mitral, or tricuspid value repair or
replacement or ventricular aneurysm repair concurrently with
their coronary artery bypass graft; and season and year of
admission.
We identified the presence of chronic comorbid conditions by
usingdischargediagnosesincludingchronichypertension,liver
disease, chronic obstructive pulmonary disease and allied
conditions,malignancy,previousmyocardialinfarction,previous
stroke, endocarditis, peripheral vascular disease, chronic renal
disease, chronic hemostatic disorder, smoking (either past or
current), alcohol/drug misuse or dependence, carotid artery
stenosis, gastrointestinal reflux, and diabetes.
21 Although these
conditions were recorded as discharge diagnoses, all of these
conditions would have been present before admission. We also
calculatedtheRomanomodificationoftheCharlsoncomorbidity
index for each patient by using conditions identified by
discharge diagnoses.
22
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RESEARCHWe evaluated markers of the severity of the patients’
preoperative cardiac and coexisting disease with charges for
drugsandproceduresbeforethedayofsurgery.Theseincluded
theuseofdrugsincludingβblockers,calciumchannelblockers,
aspirin,Aggrenoxoraspirin/dipyridamole,clopidogrel,statins,
nitrates, fibrates, digoxin, insulin, oral anti-diabetes drugs,
rhythm control drugs, warfarin, glycoprotein IIb/IIIa inhibitor,
thiazidediuretics,loopdiuretics,angiotensinconvertingenzyme
inhibitors, angiotensin receptor blockers, aldosterone
antagonists, direct renin inhibitors, systemic corticosteroids,
inhaled steroids, leukotriene inhibitors, theophylline, inhaled
β2 agonists, probiotics, sucralfate, heparin, nitroglycerine, and
inotropicsupportdrugs.Wealsoassessedchargesforprocedures
that might indicate severity of cardiac and coexisting disease,
including preoperative intensive care unit admission, cardiac
resuscitation, oxygen use, telemetry, echocardiography,
percutaneous angioplasty or stent, continuous positive airway
pressure, mechanical ventilation, or dialysis. Finally, we
determined the number of days the patient was in the hospital
before surgery.
We also assessed the characteristics of the hospitals in which
patients were treated. We recorded whether they were teaching
hospitals and whether they were located in an urban or rural
location.Weestimatedtheannualizedvolumeofcoronaryartery
bypass graft surgeries performed by each hospital by dividing
the total number of such surgeries for each hospital during the
study time period by the number of years that each hospital
performedoneormorecoronaryarterybypassgraftoperations.
We ranked hospitals in order of annualized volume and then
categorized them into thirds of volume (high, medium, and low
volume hospitals).
23 We classified the region of the hospital as
Midwest, Northeast, South, or West.
Statistical analysis
Wedeterminedbaselinecharacteristicsforthepatientsexposed
to proton pump inhibitors and H2 receptor antagonists and
summarized them as medians and interquartile ranges for
continuousvariablesandcountsandproportionsforcategorical
variables. We determined the unadjusted risk and unadjusted
risk ratios with 95% confidence intervals for postoperative
pneumonia during the index hospital admission, comparing
patients exposed to proton pump inhibitors with those exposed
toH2receptorantagonistsduringthedefinedexposurewindow.
Because of the low event rate, we report the odds ratios from
logistic regression analyses as relative risks.
24
Propensity score analyses
To account for potentially important baseline differences in
those patients who received proton pump inhibitors and H2
receptor antagonists, we did two separate propensity score
analyses. For both analyses, we first estimated a propensity
score by using a logistic regression model in which exposure
to a proton pump inhibitor (as opposed to an H2 receptor
antagonist) was the dependent variable and was estimated on
thebasisofalldemographicandsurgerycharacteristics,chronic
comorbid conditions, markers of the severity of the cardiac
condition, markers of coexisting disease/disease severity, and
hospitalcharacteristics,asdefinedabove.Themodelpredicting
exposure to a proton pump inhibitor had an area under the
receiver operating curve of 0.70 (possible range 0.5 to 1.0).
Intheprimarypropensityscoreanalysis,weexcludedallpatients
with a propensity score value that corresponded to the 2.5th
centile or lower in the proton pump inhibitor exposed patients
and to the 97.5th centile or higher in the H2 receptor antagonist
exposed patients. This technique of trimming patients in the
tailsofthepropensityscoredistributionexcludespatientstreated
strongly contrary to expectation (for example, a patient who
was strongly predicted to receive a proton pump inhibitor but
received an H2 receptor antagonist instead) and thus reduces
residualconfounding.
25Wecalculatedtenthsofpropensityscore
among the remaining patients (n=18 573; 87.6% of total). We
then fitted a multivariable logistic regression model including
indicatoroftenthofpropensityscoreasacovariate,fromwhich
we estimated a relative risk and 95% confidence interval for
postoperativepneumoniaassociatedwithprotonpumpinhibitor
exposure.
In the second propensity score analysis, we matched patients
exposed to proton pump inhibitors to those exposed to H2
receptor antagonists in a fixed 1:1 ratio by using a nearest
neighboralgorithmwithamaximummatchingdistanceof0.05.
Matching was restricted to patients undergoing coronary artery
bypass grafting in the same year. After matching, the cohort
included 15 074 patients (71.1% of original cohort). We again
estimated a relative risk and 95% confidence interval for
postoperative pneumonia.
Instrumental variable analysis
When hospitals show a strong consistency in whether they use
either proton pump inhibitors or H2 receptor antagonists for
prophylaxis,thedecisiontoadministeroneortheotherofthese
agents may be assumed to be made largely independently of
individual patients’ characteristics; in this scenario, a patient’s
receipt of either regimen is determined more strongly by the
facility at which he or she is treated than by his or her specific
risk factors. In such a circumstance, the hospital’s preferred
agent can act as an instrumental variable, thus setting the stage
for a “natural experiment” that allows for an unbiased estimate
of the risk of pneumonia, even in the presence of unmeasured
confounding.
18 26-28 This analysis assumes that patients’ choice
of hospital is made independently of the hospital’s choice of
acid suppressive drug for prophylaxis, and the hospital’s use of
proton pump inhibitors or H2 receptor antagonists is largely
independent of markers for positive or negative outcomes in
that facility. We note that these assumptions, although strong,
are distinct from the assumption of no residual confounding
that is needed for a causal interpretation of a “conventional”
analysis. A consistent result from the instrumental variable
analysis may serve as a useful confirmatory analysis for our
primary conventional approach.
Weanalyzed15800patientswhoreceivedeitheraprotonpump
inhibitor or an H2 receptor antagonist and who were treated at
hospitalsthatperformed,onaverage,atleast12coronaryartery
bypass graft procedures (average of one a month) during the
yearofsurgery.Weclassifiedhospitalsthatadministeredproton
pump inhibitors to 90% or more of their coronary artery bypass
graft patients in a given year as hospitals with a preference for
protonpumpinhibitorsandthosethatadministeredprotonpump
inhibitors to 10% or fewer of their coronary artery bypass graft
patients in a given year as hospitals that prefer H2 receptor
antagonists. Using the hospitals’ preference as an instrumental
variable, we computed differences in risk of postoperative
pneumonia between the proton pump inhibitor and H2 receptor
antagonist groups. We did this by using a two stage linear
regressionthat,forrobustness,alsoadjustedforthedemographic
and surgery characteristics, chronic comorbid conditions,
markers of the severity of the cardiac condition, and markers
of coexisting disease/disease severity. To account for any
possiblelinkbetweenhospitals’choiceofacidsuppressivedrug
for prophylaxis and positive or negative outcomes in that
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RESEARCHhospital, we additionally adjusted for the hospitals’
characteristicsandprocedurevolumemeasurementnotedabove.
Using Stata version 10 and the ivreg2 procedure, we estimated
a risk difference and number needed to harm and their 95%
confidence intervals.
Secondary outcomes, exposure subgroup, and
sensitivity analyses
We repeated each of the analyses described above to examine
the secondary outcomes of postoperative gastrointestinal
hemorrhage and in-hospital mortality. We also compared the
risk of the primary outcome in patients exposed to the most
commonly prescribed H2 receptor antagonist in our cohort,
famotidine, and the most commonly prescribed proton pump
inhibitor, pantoprazole, to test whether the main study findings
applied specifically to the most commonly used agents in each
class.Wedidasensitivityanalysisexcludingthosepatientswho
were discordant with respect to the class of acid suppressive
drugreceivedonthedayofsurgeryandduringthepostoperative
period (that is, patients who received an H2 receptor antagonist
on the day of surgery and a proton pump inhibitor during the
exposure window, or vice versa).
Lastly, we tested the generalizability of our findings to all
coronary artery bypass graft patients by examining the risk of
pneumonia in patients who underwent surgery on hospital day
1 and hospital day 2. Although important in establishing
generalizability, estimates from these analyses are more likely
to be biased than are those obtained in the primary analysis.
This is due to more limited ability to control for confounding
bias(aslessbaselineinformationisavailableonpatientsbefore
surgery) and greater likelihood of misclassification bias (as
patients taking a proton pump inhibitor or an H2 receptor
antagonist as outpatients may switch classes on admission, but
their risk of pneumonia may still be affected by the drug class
they took before admission, whereas in the primary analysis a
two day washout period exists for anyone exposed before
admission). The propensity score for patients having surgery
on day 1 included information on demographic characteristics,
surgery characteristics, chronic comorbid conditions, and
hospital characteristics. For patients having surgery on hospital
day 2, we performed all of the exclusions that were done in the
main analysis and the propensity score model included all of
thecovariatesusedinthemainanalysis(althoughmeasuredfor
a shorter period). Finally, to assess the potential effects of
residual confounding, we determined the strength
(confounder-outcome relative risk) of a hypothetical residual
confounder whose existence would produce the estimate of the
effect of proton pump inhibitors on the risk of pneumonia
observedintheprimaryanalysis.
29Astheeffectofconfounders
varieswithrelativeprevalence,weassumedaprevalenceof5%
among the unexposed patients and range of prevalences in the
exposed patients.
Results
Cohort characteristics
Our primary cohort consisted of 21 214 patients who had
coronary artery bypass grafting between 2004 and 2010, of
whom 11 384 (53.7%) received H2 receptor antagonists and
9830 (46.3%) received proton pump inhibitors (figure⇓).
Postoperative length of stay was the same in the two exposure
groups (median 5 (interquartile range 4-7) days), thus giving
us an equal opportunity to observe outcomes in both groups.
The number of days of exposure to acid suppressive treatment
(including the day of surgery) was similar for the two exposure
groups (H2 receptor antagonists median 6 (4-7) days; proton
pump inhibitors median 6 (4-8) days). Overall, 979 (4.6%) of
patients developed postoperative pneumonia, a figure that is in
line with previously published estimates.
1-5 Postoperative
pneumoniawasstronglyassociatedwithadverseoutcomes;101
(10.3%) of patients with postoperative pneumonia died during
theindexhospitaladmissioncomparedwith2321.1%ofpatients
whodidnotdeveloppneumonia.Pneumoniawasalsoassociated
with substantially longer length of hospital admission (median
length of stay 18 (12-29) days for patients with pneumonia
versus 9 (8-12) days for those without pneumonia).
Baseline characteristics
In general, baseline characteristics were similar in patients
exposed to proton pump inhibitors and H2 receptor antagonists;
however, some differences existed that had the potential to
confound the analysis (table 1⇓). Patients exposed to proton
pump inhibitors were more often white and were treated more
commonlyatteachinghospitalsandathospitalsintheNortheast.
Proton pump inhibitor exposed patients more frequently had
their coronary artery bypass graft done on cardiopulmonary
bypass. They more often received supplemental oxygen and
monitoring with telemetry but were less often in the intensive
care unit preoperatively. They received aspirin less often, but
moreoftenreceivedintravenousheparin.Afterpropensityscore
matching,thesedifferenceswerenolongerpresent.Furthermore,
after propensity score matching, the proportion of patients who
were mechanically ventilated was the same in the two groups
(0.7%), as was the duration of ventilation (for those who were
ventilated, median 3 (2-4) days).
Association of type of stress ulcer
prophylaxis with postoperative pneumonia
Overall, 492 (5.0%) of the proton pump inhibitor exposed and
487 (4.3%) of the H2 receptor antagonist exposed patients
developed postoperative pneumonia (unadjusted relative risk
ratio1.17,95%confidenceinterval1.04to1.32;riskdifference
per1000cases7.3,1.6to13.0).Inthepropensityscorestratified
analysis (table 2⇓), the increased risk of postoperative
pneumonia remained (risk ratio 1.19, 1.03 to 1.38). The
propensityscorematchedanalysisyieldedasimilarthoughless
precise estimate (risk ratio 1.14, 0.99 to 1.32; risk difference
6.1, −0.6 to 12.8). In the multivariable instrumental variable
analysis (table 3⇓), the use of proton pump inhibitors was
associated with an increased absolute difference in risk of
pneumoniaof8.2(0.5to15.9)per1000patientscomparedwith
the use of H2 receptor antagonists, which corresponded to a
number needed to harm of 122 (95% confidence interval 63 to
1946). The multivariable adjusted risk ratio estimates for the
mostcommonlyusedprotonpumpinhibitor(pantoprazole)and
the most commonly used H2 receptor antagonist (famotidine)
were not meaningfully different from the overall results (table
4⇓).
Three hundred sixty nine patients in the H2 receptor antagonist
group were exposed to proton pump inhibitors on the day of
surgery, and 2388 patients in the proton pump inhibitor group
were exposed to H2 receptor antagonists. When we excluded
these patients and repeated our primary analysis, assessing the
risk of pneumonia by using propensity score stratified analysis,
the results did not meaningfully change (risk ratio 1.19, 1.01 to
1.40).
In all, 69 767 patients had coronary artery bypass graft surgery
on hospital day 1 and were exposed to proton pump inhibitors
or H2 receptor antagonists on postoperative day 1 or 2. The
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RESEARCHpropensity score stratified analysis suggested that proton pump
inhibitors increased the risk of pneumonia in this group as well
(risk ratio 1.11, 1.02 to 1.20). After the relevant exclusions, 25
855patientshadcoronaryarterybypassgraftsurgeryonhospital
day2andwereexposedtoprotonpumpinhibitorsorH2receptor
antagonists. Again, after propensity score stratification, proton
pump inhibitors were associated with an increased risk of
pneumonia, albeit with a more modest effect size than that
observed in our other analyses and with a confidence interval
that intersected the null (risk ratio 1.06, 0.93 to 1.21).
Weestimatedthestrengthofahypotheticalresidualconfounder
that could have produced the observed effect of proton pump
inhibitors on the risk of pneumonia from the primary analysis
(risk ratio 1.19). Given a prevalence of the confounder of 5%
in the H2 receptor antagonist exposed population, a
confounder-outcome risk ratio of 5.7 would be needed if the
prevalence of the confounder in the proton pump inhibitor
exposedpopulationwas10%,ariskratioof2.4iftheprevalence
was 20%, and a risk ratio of 1.8 if the prevalence was 30%. The
supplementary figure shows values of strength across a range
of prevalence values.
Association of type of stress ulcer
prophylaxis with upper gastrointestinal
hemorrhage and in-hospital mortality
Overall, 154 (1.57%) proton pump inhibitor exposed and 179
(1.57%) H2 receptor antagonist exposed patients died, and 16
(0.16%) proton pump inhibitor exposed and 19 (0.17%) H2
receptor antagonist exposed patients had gastrointestinal
hemorrhagerequiringesophagogastroduodenoscopy.Confidence
intervals for both analyses were wide and included the null
(table 5⇓).
Discussion
Using a hospital based cohort of 21 214 patients who had
coronary artery bypass graft surgery, we found a small but
clinically meaningful increase in the risk of postoperative
pneumonia in patients treated with proton pump inhibitors
compared with those treated with H2 receptor antagonists for
stress ulcer prophylaxis in the postoperative period. This
increase in risk persisted despite application of several distinct
techniques to identify and account for potentially confounding
characteristics of patients and hospitals that might affect the
selectionofagentforstressulcerprophylaxis,includingtheuse
of propensity score stratification, propensity score matching,
and instrumental variable analysis. Furthermore, when we
compared patients who received the most commonly
administered proton pump inhibitor and H2 receptor antagonist
(pantoprazole and famotidine), the observed increase in risk
associated with exposure to proton pump inhibitor remained.
Although the 15-19% increase in risk of postoperative
pneumonia that we observed associated with proton pump
inhibitors compared with H2 receptor antagonists is small, our
data favor, all other factors being equal, the selection of H2
receptorantagonistsoverprotonpumpinhibitorsforstressulcer
prophylaxis in the postoperative period for coronary artery
bypass graft patients.
Comparison with other studies
The magnitude of the increase in risk of pneumonia associated
with proton pump inhibitors that we observed is substantially
smaller than the risk found in the largest previous study that
compared the risk of proton pump inhibitors versus H2 receptor
antagonistsincardiothoracicsurgicalpatients.Thesinglecenter,
retrospectivecohortstudyinvolving887patientsfoundpatients
treated with pantoprazole to have a remarkable 2.7-fold higher
oddsofpneumoniacomparedwiththosetreatedwithranitidine,
after adjustment for confounding factors.
10 Several factors may
accountforthedifferencebetweenourstudyandthesefindings.
Firstly, because the earlier study was conducted at a single
center, the decision to use an a proton pump inhibitor versus an
H2receptorantagonistwaslikelymoredependentonindividual
patients’ characteristics, thus creating susceptibility to
confounding, than it was in our large, multicenter sample in
whichmuchofthevariabilityinselectionofagentlikelyderived
fromphysician/hospitalguidelinesorpreference.Secondly,the
range of patients’ characteristics and comorbidities captured
and adjusted for in this previous analysis was not as extensive
as what we were able to capture using the Premier dataset.
Finally, the 95% confidence intervals in this previous analysis
were very wide (1.1 to 6.7) and intersect with the estimate of
pneumonia risk associated with proton pump inhibitors versus
H2 receptor antagonists in our study.
The small increase in risk of pneumonia that was observed is
consistent with other studies that have examined proton pump
inhibitorsandH2receptorantagonistsforstressulcerprophylaxis
incriticalcareandgeneralhospitalsettings.Arecentlypublished
meta-analysisofrandomizedcontrolledclinicaltrialscomparing
the two drug classes for stress ulcer prophylaxis in critically ill
patients identified seven trials with a total of 1017 patients; the
point estimate for the development of nosocomial pneumonia
associated with proton pump inhibitor treatment was slightly
elevated, but with wide 95% confidence intervals (odds ratio
1.05, 0.69 to 1.62), which led the authors to conclude that there
wasnoincreaseinrisk.
30Similarly,inacohortstudycomparing
the risk of hospital acquired pneumonia associated with acid
suppressivedrugscomparedwithnon-exposuretotheseagents,
the risk estimate (compared with no stress ulcer prophylaxis)
wasslightlyhigherintheprotonpumpinhibitorexposedpatients
than in those exposed to H2 receptor antagonists (odds ratio 1.3
v 1.2).
11
Possible explanations and implications
The increased risk of postoperative pneumonia associated with
proton pump inhibitors versus H2 receptor antagonists is
biologically plausible. Gastrointestinal bacterial overgrowth is
greater in patients treated with proton pump inhibitors,
9
presumablyduetogreateracidsuppression.
10Thismay,inturn,
predispose to microaspiration of bacterial gastrointestinal
contents and pneumonia. Furthermore, evidence shows that
proton pump inhibitors impair immune cell function,
31-34 which
is another potential mechanism to explain the differential risk
that we observed.
11
In our study, treatment with the two classes of acid suppressive
drug was associated with similar risk of postoperative
gastrointestinal hemorrhages (although, in the setting of few
events, confidence intervals are wide). Randomized trials
comparing proton pump inhibitors and H2 receptor antagonists
in critically ill patients generally show a decrease in clinically
significant bleeding associated with the use of proton pump
inhibitors.
30 Several conditions that are important risk factors
for gastrointestinal hemorrhage are not accurately captured in
the Premier database, including a history of previous
gastrointestinal hemorrhage or known peptic ulcer disease; our
effectestimatesforthisendpointmaythusbesubjecttoresidual
unmeasured confounding. However, upper gastrointestinal
hemorrhage was very infrequent in our cohort, and all of the
affected patients were taking some form of stress ulcer
prophylaxis, with an overall incidence of 0.2% based on a
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RESEARCHdefinition that required a diagnostic code indicating
gastrointestinal bleeding and a charge code indicating
esophagogastroduodenoscopy.Althoughnotallgastrointestinal
bleeding will result in an endoscopy (which may result in some
under-ascertainmentofthisoutcomeinourstudy),
35hemorrhage
that results in hemodynamic instability or hematemesis will
generally result in an endoscopy, suggesting that our definition
captures the most clinically significant bleeding events. This
incidenceof0.2%contrastswiththeincidenceofpostoperative
pneumonia that we observed of 4.6%. Given the substantially
higher incidence of postoperative pneumonia, coupled with the
fact that upper gastrointestinal bleeds are generally, in and of
themselves, not lethal,
30 36 the risk of pneumonia may be the
more important consideration in choosing the agent for stress
ulcer prophylaxis in this patient population. This is supported
by a trend toward higher mortality associated with treatment
withprotonpumpinhibitorsinourstudy.Thatsaid,astrialdata
suggest that proton pump inhibitors seem to be more effective
inpreventingclinicallyimportantuppergastrointestinalbleeding
in critically ill patients,
37 and sepsis guidelines recommend that
proton pump inhibitors be used rather than H2 receptor
antagonists,
38 future research will need to determine how to
balance the possible slightly increased risk of pneumonia
associated with proton pump inhibitors compared with H2
receptor antagonists with the decreased risk of stress ulcers in
specific patient populations.
Limitations of study
Ourstudyshouldbeinterpretedinthecontextofthelimitations
inherentinitsdesign.AlthoughthePremierResearchDatabase
captures detailed information on inpatient drug treatment and
procedureutilization,laboratorytesting,andpatients’diagnoses,
this is administrative information collected for billing purposes
and not expressly for research, and it thus lacks certain relevant
clinicaldetails.Werigorouslyattemptedtoidentifyandaccount
for all relevant confounders in the available data that might
influence the decision to administer a proton pump inhibitor
versus an H2 receptor antagonist, but the possibility exists, as it
does in all observational studies, that the results from our main
analysis might be biased by unknown or unmeasured
confounders. To minimize this limitation, we also did an
instrumental variable analysis. In this analysis, we examined
the subsample of hospitals that showed a strong preference for
one or the other acid suppressive drug type (with at least 90%
of patients receiving one or the other agent, presumably on the
basis of a formulary or protocol), with preference acting as an
instrument. The choice of agent in this circumstance is not
dependent on characteristics of individual patients and is thus
not subject to unmeasured confounding. The fact that the
instrumental variable analysis—an analysis based on strong
assumptions but different ones than the “conventional”
approach—showsanincreasedriskofpostoperativepneumonia
associated with proton pump inhibitors, suggests that this
association is unlikely to be a consequence of unmeasured
confounding. Furthermore, the sensitivity analysis for
unmeasured confounding suggested that an unmeasured
confounder would need to have relatively strong associations
with both proton pump inhibitor versus H2 receptor antagonist
use and pneumonia to fully explain the results seen in the main
analysis. However, the observed excess risk of pneumonia
associated with proton pump inhibitors is very small, with
confidence intervals that are very close to one, and this should
be considered when interpreting these results.
An additional limitation is that we did not have access to direct
clinical data such as chest radiograph findings, white blood cell
counts, and sputum cultures to define the occurrence of
postoperative pneumonia, but rather were dependent on the
coding of this complication in the discharge abstract. The
specificity for the recording of pneumonia in administrative
data seems to be high (although these validations studies did
not specifically examine postoperative pneumonia).
39 40
Furthermore, any misclassification of the outcome is likely to
benon-differentialbetweenthetwogroups,suchthatourrelative
risk estimates would be biased, if anything, to the null.
Under-coding or misclassification is thus unlikely to be able to
account for the increased risk associated with proton pump
inhibitors that we observed.
A further limitation is that, to establish baseline measures of
comorbidities that might affect the decision to administer a
proton pump inhibitor or an H2 receptor antagonist, we did our
primary analysis on those patients who had surgery on hospital
day 3 or later. To ensure that the diagnosis of pneumonia
occurred during the postoperative period, we further excluded
patients who were exposed to antibiotics before surgery (which
might be used to treat pneumonia if diagnosed preoperatively).
We also excluded patients exposed to acid suppressive drugs
before the day of surgery to isolate the effect of these drugs as
administered in the immediate postoperative period. While
recognizingthatoureffectestimatesaremorelikelytobesubject
to bias than are those of the main analysis, we also examined
theriskofpneumoniaassociatedwithexposuretoprotonpump
inhibitors in patients who had surgery on hospital day 1 or 2.
In both of these analyses, proton pump inhibitors were again
associated with increased risk of pneumonia, suggesting that
our results are generalizable to all coronary artery bypass graft
patients. That said, the estimates of the effect of proton pump
inhibitors on the risk of pneumonia for patients who had
coronary artery bypass graft surgery on hospital days 1 or 2
wereclosertothenullthanwasobservedintheprimaryanalysis
(which may be a result of residual confounding of the estimate,
greater exposure misclassification among patients with surgery
earlier in the hospital admission (owing to exposure before
admission), or effect modification by timing of surgery).
Conclusion
Our analysis suggests a 15-19% increase in the risk of
postoperative pneumonia associated with the administration of
proton pump inhibitors compared with H2 receptor antagonists
intheimmediatepostoperativeperiodincoronaryarterybypass
graft patients. Given the importance of the complication of
postoperative pneumonia in this patient population, clinicians
should consider this differential risk when selecting the type of
agent used for stress ulcer prophylaxis.
Contributors: BTB and KB were involved in all parts of the study. JAR
was involved in designing the study, data analysis, and writing the
manuscript. MD was involved in data analysis and revising the
manuscript. NKC, SS, JJG, JMP, JMF, and MAF were involved in
designing the study and revising the manuscript. BTB and KB are the
guarantors.
Funding source: JAR is a recipient of a career development award from
the Agency for Healthcare Research and Quality (K01 HS018088).
Competing interests: All authors have completed the ICMJE uniform
disclosure form at www.icmje.org/coi_disclosure.pdf (available on
request from the corresponding author) and declare: SS is principal
investigator of the Brigham and Women’s Hospital DEcIDE Center on
Comparative Effectiveness Research and the DEcIDE Methods Center,
both funded by the Agency for Healthcare Research and Quality, and
of the Harvard-Brigham Drug Safety and Risk Management Research
Center funded by the Food and Drug Administration; SS is a paid
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2013;347:f5416 doi: 10.1136/bmj.f5416 (Published 19 September 2013) Page 6 of 14
RESEARCHWhat is already known on this topic
Each year, approximately 800 000 patients have coronary artery bypass graft surgery (CABG) worldwide, making it one of the most
commonly performed operative procedures
Proton pump inhibitors and H2 receptor antagonists are acid suppressing agents that are frequently administered after CABG for stress
ulcer prophylaxis
Postoperative pneumonia is a common and highly morbid complication following CABG
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RESEARCHTables
Table 1| Selected baseline characteristics of study patients treated with either proton pump inhibitors (PPI) or H2 receptor antagonists
(H2RA) for stress ulcer prophylaxis after coronary artery bypass grafting. Values are numbers (percentages) unless stated otherwise
IV analysis After PS matching Before PS matching
H2RA preference
(n=7103)
PPI preference
(n=8697) H2RA (n=7537) PPI (n=7537) H2RA (n=11 384) PPI (n=9830)
Demographic characteristics
66.0 (58.0-74.0) 66.0 (57.0-74.0) 66.0 (58.0-74.0) 66.0 (58.0-74.0) 66.0 (57.0-74.0) 66.0 (58.0-74.0) Median (IQR) age
Ethnicity:
5383 (75.8) 5970 (68.6) 5422 (71.9) 5441 (72.2) 7896 (69.4) 7318 (74.4) White
396 (5.6) 684 (7.9) 482 (6.4) 490 (6.5) 850 (7.5) 573 (5.8) Black
276 (3.9) 427 (4.9) 338 (4.5) 336 (4.5) 556 (4.9) 387 (3.9) Other
1766 (24.9) 2462 (28.3) 1999 (26.5) 1968 (26.1) 3114 (27.4) 2516 (25.6) Female sex
Surgical characteristics
Type of admission:
5077 (71.5) 5905 (67.9) 5281 (70.1) 5234 (69.4) 7796 (68.5) 7064 (71.9) Emergency
1970 (27.7) 2719 (31.3) 2207 (29.3) 2261 (30.0) 3504 (30.8) 2699 (27.5) Elective
56 (0.8) 73 (0.8) 49 (0.7) 42 (0.6) 84 (0.7) 67 (0.7) Unknown
6154 (86.6) 6877 (79.1) 6264 (83.1) 6294 (83.5) 9093 (79.9) 8460 (86.1) Surgery done with
cardiopulmonary
bypass
Comorbidities
2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) 2.0 (1.0-3.0) Median (IQR)
Charlson comorbidity
score
5466 (77.0) 6875 (79.1) 5893 (78.2) 5902 (78.3) 8921 (78.4) 7599 (77.3) Chronic hypertension
1547 (21.8) 2078 (23.9) 1709 (22.7) 1664 (22.1) 2662 (23.4) 2153 (21.9) Chronic obstructive
pulmonary disease
and allied conditions
1138 (16.0) 1335 (15.4) 1167 (15.5) 1168 (15.5) 1722 (15.1) 1544 (15.7) Previous myocardial
infarction
800 (11.3) 716 (8.2) 746 (9.9) 739 (9.8) 929 (8.2) 1074 (10.9) Chronic renal disease
2921 (41.1) 3633 (41.8) 3084 (40.9) 3095 (41.1) 4721 (41.5) 3988 (40.6) Diabetes
Inpatient use of drugs and services before surgery
6087 (85.7) 7223 (83.1) 6407 (85.0) 6372 (84.5) 9511 (83.5) 8392 (85.4) β blocker
4848 (68.3) 6545 (75.3) 5456 (72.4) 5424 (72.0) 8442 (74.2) 6830 (69.5) Aspirin
1169 (16.5) 1585 (18.2) 1300 (17.2) 1307 (17.3) 2012 (17.7) 1642 (16.7) Clopidogrel
5518 (77.7) 6270 (72.1) 5641 (74.8) 5642 (74.9) 8214 (72.2) 7496 (76.3) Statin
4156 (58.5) 5216 (60.0) 4534 (60.2) 4495 (59.6) 6916 (60.8) 5818 (59.2) Nitrates
2073 (29.2) 2200 (25.3) 2060 (27.3) 2055 (27.3) 2959 (26.0) 2811 (28.6) Insulin
2450 (34.5) 2816 (32.4) 2503 (33.2) 2516 (33.4) 3731 (32.8) 3330 (33.9) Oral anti-diabetes
drugs
3387 (47.7) 4078 (46.9) 3595 (47.7) 3574 (47.4) 5391 (47.4) 4623 (47.0) Angiotensin converting
enzyme inhibitor
733 (10.3) 912 (10.5) 789 (10.5) 794 (10.5) 1216 (10.7) 1004 (10.2) Inhaled β2 agonists
3810 (53.6) 3768 (43.3) 3552 (47.1) 3518 (46.7) 4930 (43.3) 5008 (50.9) Intravenous heparin
1504 (21.2) 2357 (27.1) 1866 (24.8) 1862 (24.7) 3066 (26.9) 2192 (22.3) Intravenous
nitroglycerin
589 (8.3) 605 (7.0) 613 (8.1) 602 (8.0) 858 (7.5) 909 (9.2) Intravenous inotropes
3347 (47.1) 4844 (55.7) 3850 (51.1) 3827 (50.8) 6369 (55.9) 4692 (47.7) Intensive care unit
admission
24 (0.3) 35 (0.4) 26 (0.3) 26 (0.3) 52 (0.5) 34 (0.3) Cardiac resuscitation
3019 (42.5) 3460 (39.8) 3115 (41.3) 3057 (40.6) 4563 (40.1) 4067 (41.4) Echocardiography
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RESEARCHTable 1 (continued)
IV analysis After PS matching Before PS matching
H2RA preference
(n=7103)
PPI preference
(n=8697) H2RA (n=7537) PPI (n=7537) H2RA (n=11 384) PPI (n=9830)
42 (0.6) 63 (0.7) 49 (0.7) 50 (0.7) 79 (0.7) 60 (0.6) Mechanical ventilation
95 (1.3) 123 (1.4) 113 (1.5) 107 (1.4) 153 (1.3) 146 (1.5) Dialysis
Hospital characteristics
4387 (61.8) 4128 (47.5) 4014 (53.3) 4007 (53.2) 5566 (48.9) 5798 (59.0) Teaching hospital
6584 (92.7) 8099 (93.1) 6954 (92.3) 6955 (92.3) 10 614 (93.2) 9036 (91.9) Urban hospital
IQR=interquartile range; IV=instrumental variable; PS=propensity score.
Age was modeled as categorical variable in propensity score/instrumental variable models. Additional covariates that were included in propensity score/instrumental
variable models and balanced after matching include marriage status; number of grafts; previous coronary artery bypass graft (CABG); mammary graft; packed
red blood cell transfusion; intra-aortic balloon pump placement; aortic, mitral, or tricuspid valve replacement or repair; ventricular aneurysm repair; chronic liver
disease; cancer; previous stroke; previous endocarditis; peripheral vascular disease; chronic hemostatic disorder; smoking; alcohol or drug misuse; carotid artery
stenosis; gastroesophageal reflux disease; calcium channel blockers; aspirin/dipyridamole; fibrates; digoxin; rhythm control drugs; warfarin; glycoprotein IIb/IIIa
inhibitor; thiazide diuretics; loop diuretics; angiotensin receptor blockers; aldosterone antagonists; direct renin inhibitor; systemic steroids; inhaled steroids;
leukotriene inhibitors; theophylline; probiotics; sucralfate; oxygen use; telemetry; percutaneous angioplasty or stent; continuous positive airway pressure; preoperative
length of stay; third of CABG volume; and region.
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RESEARCHTable 2| Relative risk of postoperative pneumonia in patients undergoing coronary artery bypass graft surgery treated with proton pump
inhibitors (PPI) compared with H2 receptor antagonists (H2RA)
Risk difference (95% CI) per 1000 patients Risk ratio (95% CI)
No of outcomes/No of patients
Analysis H2RA PPI
7.3 (1.6 to 13.0) 1.17 (1.04 to 1.32) 487/11 384 492/9830 Unadjusted
— 1.19 (1.04 to 1.36) 487/11 384 492/9830 Age, sex, race, calendar year adjusted
— 1.19 (1.03 to 1.38) 421/10 059 411/8514 Propensity score tenths stratified
6.1 (−0.6 to 12.8) 1.14 (0.99 to 1.32) 323/7537 369/7537 Propensity score matched
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RESEARCHTable 3| Instrumental variable estimates of risk differences of postoperative pneumonia for patients treated with proton pump inhibitors
compared with H2 receptor antagonists
Risk difference per 1000 patients (95% CI) Model
7.0 (0.2 to 13.9) Crude model
8.2 (1.1 to 15.4) Age, sex, race, calendar year adjusted model
8.2 (0.5 to 15.9) Propensity score tenths adjusted model
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RESEARCHTable 4| Relative risk of postoperative pneumonia in patients undergoing coronary artery bypass graft surgery treated with pantoprazole
compared with famotidine
Risk difference (95% CI) per 1000 patients Risk ratio (95% CI)
No of outcomes/No of patients
Analysis Famotidine Pantoprazole
4.3 (−2.0 to 10.6) 1.10 (0.96 to 1.26) 448/10 253 350/7295 Unadjusted
— 1.13 (0.97 to 1.30) 448/10 253 350/7295 Age, sex, race, calendar year adjusted
— 1.15 (0.98 to 1.35) 391/9157 293/6243 Propensity score tenths stratified
6.7 (−0. 8 to 14.2) 1.16 (0.98 to 1.37) 250/5931 290/5931 Propensity score matched
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RESEARCHTable 5| Relative risk of postoperative gastrointestinal hemorrhage and in-hospital mortality in patients undergoing coronary artery bypass
graft surgery treated with proton pump inhibitors (PPI) compared with H2 receptor antagonists (H2RA)
Risk difference (95% CI) per 1000
patients Risk ratio (95% CI)
No of outcomes/No of patients
Outcome and analysis H2RA PPI
Gastrointestinal bleed with esophagogastroduodenoscopy:
0 (−1.1 to 1.1) 0.98 (0.50 to 1.90) 19/11 384 16/9830 Unadjusted
— 1.05 (0.53 to 2.08) 19/11 384 16/9830 Age, sex, race, calendar year adjusted
— 0.96 (0.46 to 2.01) 18/10 059 14/8514 Propensity score tenths stratified
0.4 (−0.8 to 1.6) 1.30 (0.57 to 2.96) 10/7537 13/7537 Propensity score matched
Death:
−0.1 (−3.4 to3.3) 1.00 (0.81 to 1.23) 179/11 384 154/9830 Unadjusted
— 1.09 (0.87 to 1.36) 179/11 384 154/9830 Age, sex, race, calendar year adjusted
— 1.15 (0.90 to 1.47) 150/10 059 134/8514 Propensity score tenths stratified
1.3 (−2.7 to 5.3) 1.09 (0.85 to 1.40) 116/7537 126/7537 Propensity score matched
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RESEARCHFigure
Flow of patients through study. CABG=coronary artery bypass graft; H2RA=H2 receptor antagonist; PPI=proton pump
inhibitor.
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